Search hospitals > Florida > Miami

University of Miami Miller School of Medicine-Sylvester Cancer Center

Claim this profile
Miami, Florida 33136
Global Leader in Cancer
Global Leader in Lung Cancer
Conducts research for Breast Cancer
Conducts research for Brain Tumor
Conducts research for Lymphoma
793 reported clinical trials
85 medical researchers
Photo of University of Miami Miller School of Medicine-Sylvester Cancer Center in MiamiPhoto of University of Miami Miller School of Medicine-Sylvester Cancer Center in MiamiPhoto of University of Miami Miller School of Medicine-Sylvester Cancer Center in Miami

Summary

University of Miami Miller School of Medicine-Sylvester Cancer Center is a medical facility located in Miami, Florida. This center is recognized for care of Cancer, Lung Cancer, Breast Cancer, Brain Tumor, Lymphoma and other specialties. University of Miami Miller School of Medicine-Sylvester Cancer Center is involved with conducting 793 clinical trials across 803 conditions. There are 85 research doctors associated with this hospital, such as Julio C Barredo, MD, Jose Lutzky, MD, Chukwuemeka (Emeka) V. Ikpeazu, and Macarena I. De La Fuente.

Area of expertise

1Cancer
Global Leader
University of Miami Miller School of Medicine-Sylvester Cancer Center has run 134 trials for Cancer. Some of their research focus areas include:
Stage IV
Stage III
Stage I
2Lung Cancer
Global Leader
University of Miami Miller School of Medicine-Sylvester Cancer Center has run 89 trials for Lung Cancer. Some of their research focus areas include:
Stage IV
Stage III
Stage II

Top PIs

Clinical Trials running at University of Miami Miller School of Medicine-Sylvester Cancer Center

Skin Cancer
Lung Cancer
Prostate Cancer
Brain Tumor
Ovarian Cancer
Pancreatic Cancer
Breast Cancer
Cancer
Testicular cancer
Melanoma
Image of trial facility.

Radiation Therapy

for Brain Metastasis

This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. FSRS delivers a high dose of radiation to the tumor over 3 treatments. SRS is a type of external radiation therapy that uses special equipment to position the patient and precisely give a single large dose of radiation to a tumor. FSRS may be more effective compared to SRS in treating patients with cancer that has spread to the brain.
Recruiting2 awards Phase 312 criteria
Image of trial facility.

Cemiplimab + Surgery

for Advanced Skin Cancer

This phase III trial compares the effect of adding cemiplimab to standard therapy (surgery with or without radiation) versus standard therapy alone in treating patients with stage III/IV squamous cell skin cancer that is able to be removed by surgery (resectable) and that may have come back after a period of improvement (recurrent). The usual treatment for patients with resectable squamous cell skin cancer is the removal of the cancerous tissue (surgery) with or without radiation, which uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Immunotherapy with monoclonal antibodies, such as cemiplimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cemiplimab has been approved for the treatment of skin cancer that has spread or that cannot be removed by surgery, but it has not been approved for the treatment of skin cancer than can be removed by surgery. Adding cemiplimab to the usual treatment of surgery with or without radiation may be more effective in treating patients with stage III/IV resectable squamous cell skin cancer than the usual treatment alone.
Recruiting2 awards Phase 37 criteria
Image of trial facility.

Immunotherapy + Prednisone + Sirolimus

for Skin Cancer

This phase II trial tests the combination of nivolumab and ipilimumab with sirolimus and prednisone for the treatment of skin (cutaneous) cancer that cannot be removed by surgery (unresectable) or that has spread from where it first started to other places in the body (metastatic) in kidney transplant recipients. Immunotherapy with nivolumab and ipilimumab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Sirolimus and prednisone are immunosuppressants that are given to keep the body from rejecting the transplanted kidney. Giving nivolumab and ipilimumab in combination with sirolimus and prednisone may kill more cancer cells, while also keeping the transplanted kidney healthy, in patients with unresectable or metastatic cutaneous cancer who have received a kidney transplant.
Recruiting1 award Phase 1 & 210 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at University of Miami Miller School of Medicine-Sylvester Cancer Center?
Where is University of Miami Miller School of Medicine-Sylvester Cancer Center located?
Who should I call to ask about financial aid or insurance network?
What insurance does University of Miami Miller School of Medicine-Sylvester Cancer Center accept?
What awards or recognition has University of Miami Miller School of Medicine-Sylvester Cancer Center received?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security